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1INTRODUCTION
Early series of pancreatic operations for cancer published in the
late 1960s reported postoperative morbidity rates of 60% and mortality
rates approaching 25% with dismal long term outcomes. Consequently,
Crile (1970) suggested that patients would be served better by a bypass
procedure, rather than a futile and risky resection. Such a nihilistic
approach was the prevailing attitude before the 1980s, to the point that
surgeons asked themselves whether pancreaticoduodenectomy should be
abandoned as treatment of pancreatic cancer (van Heerden et al, 1980).
In the ensuing decades, however, dramatic declines in surgical mortality
and morbidity rates were witnessed. High volume pancreatic surgical
centres consistently reported mortality rates of less than 2% and
morbidity rates of 36% (Buchler et al, 2003). Continual improvements
in surgical techniques have played a role, but credit cannot be claimed
solely by the surgical profession because significant advances were
achieved in tandem in other fields, including better patient selection, and
improvements in perioperative care. Perhaps one of the main
contributors to this phenomenon was the emergence of high volume
centers (Beger et al, 2003). Such centers tend to boast larger facilities
and have a broader range of specialist and technology-based services,
2with better-staffed intensive care units. The implication is that
complications are better recognized and managed.
Our hospital is a high volume centre for pancreatic surgery, and
both pancreaticogastrostomy and pancreaticojejunostomy is done after a
standard pancreaticoduodenectomy. The purpose of this study is to
analyse and evaluate the influence of perioperative factors and type of
pancreaticoenteric anastomosis after pancreaticoduodenectomy and
measure the short-term outcome in terms of morbidity and mortality.
3AIM OF THE STUDY
To analyse the pattern of morbidity and mortality between
patients undergoing pancreaticogastrostomy and pancreatico
jejunostomy for a pancreatic remnant anastomosis following a standard
pancreaticoduodenectomy.
To analyse the perioperative variables predicting the outcome and
hence formulate a standard method of patient selection, type of
anastomosis and perioperative care to achieve good outcome after a
whipple operation.
4REVIEW OF LITERATURE
Periampullary cancer includes adenocarcinoma of the head, neck,
and uncinate process of the pancreas; ampulla; distal common bile duct;
and   ampullary   duodenum.  Often,  the  precise  site  of  origin  cannot  be
determined until the tumor has been resected1. Pathologic examination
of resected pancreaticoduodenectomy specimens reveal that 40–60% are
adenocarcinomas of the head of the pancreas, 10–20% are
adenocarcinomas  of  the  ampulla  of  Vater,  10%  are  distal  bile  duct
adenocarcinomas, and 5–10% are duodenal adenocarcinomas. Since
these data represent resected specimens, and since the resectability rate
of the nonpancreatic periampullary cancers is much higher, it is likely
that pancreas is the site of origin in up to 90% of cases2.
HISTORY
Of the many indications for pancreatic resection, cancer has been
the most intensely researched and the most meticulously documented.
Ductal adenocarcinoma is the most prevalent tumor of the pancreas,
with a predominant localization within the pancreatic head (78%) 3. It is
an undisputed fact, however, that pancreatic resection ranks as one of
the most complicated and technically challenging surgical procedures
through the ages.
5The study of the history of pancreatic surgery also offers insight
into the evolution of the surgical techniques. Pancreaticoduodenectomy
probably had its origins in papillectomy, with Halsted (1899) being the
first to report a successful resection of the ampulla in 1898. This
accomplishment emboldened other investigators to experiment with
more extensive excisions of the ampulla, duodenum and pancreas. Also
in 1898, Codivilla (1898) reported the first pancreaticoduodenectomy,
which he had performed in one stage. His patient died on the 21st
postoperative day, however, from complications arising from what
seemed like a pancreatic leak4. The first successful
pancreaticoduodenectomy was performed by a German surgeon,
Kausch, 11 years after Codivilla’s landmark effort5.  Kausch, a student
of Von Mickulicz-Radecki, performed the operation in two stages. In
the first, he decompressed the biliary tree, and 6 weeks later, he
completed the extirpation and the reconstruction, including a
pancreaticoduodenal anastomosis to the third part of the duodenum.
In their 1935 landmark publication, Whipple and co-workers
reviewed their series of 80 patients who had surgical treatment for
ampullary carcinoma, among which were 2 cases of
pancreaticoduodenectomy. Whipple’s maiden attempt was a two-stage
procedure, with biliary and gastric decompression in the first stage and
6tumor extirpation in the second stage. With increasing experience.
Whipple’s technique eventually evolved into a one-stage procedure
complete with a pancreaticojejunostomy6 . This metamorphosis was
bolstered  by  the  discovery  of  Vitamin  K  in  1929  and  the  “fat
metabolizing hormone” in 1936. His one-stage innovation ensured a
clean surgical field devoid of scars and adhesions that were the
trademarks of a preliminary operation. In tribute to his efforts in this
seminal work, Hunt (1941) labeled this method Whipple’s procedure7.
Even with advances in multimodality treatment, surgery is a
crucial part, if not the centerpiece, of the treatment algorithm for
pancreatic cancer because no truly effective chemotherapeutic agents for
treating nonresectable disease have been developed yet. The American
Gastroenterological Association (1999) endorsed
pancreaticoduodenectomy as the recommended operation for patients
with resectable  tumors. Technical refinements have led to the advent of
a variety of surgical techniques that allowed a more individualized,
disease-directed approach. These modifications were partly responsible
for the decline in surgical morbidity.
EPIDEMIOLOGY AND RISK FACTORS
In 2004, an estimated 31,270 deaths were attributed  to pancreatic
cancer, making it the fourth leading cause of cancer mortality in the
7Unites States10 . There is a slightly higher incidence in men than in
women (relative risk 1.35) and in African American men (30-40%
higher). Advancing age is perhaps the stronger risk factor. The peak
incidence of pancreatic cancer is in the 60s and 70s, and mean age at
diagnosis is 60 to 65 years11. Other risk factors include Ashkenazi
Jewish heritage, cigarette smoking, diabetes mellitus, chronic
pancreatitis, obesity, low level of physical activity, and occupational
exposure to carcinogens. Six genetic syndromes have been linked to
pancreatic adenocarcinoma: hereditary pancreatitis, hereditary
nonpolyposis colorectal cancer, hereditary breast and ovarian cancer,
familial atypical multiple molemelanoma syndrome, Peutz-Jeghers
syndrome, and ataxiatelangectasia. The relationship between diabetes,
pancreatitis, and pancreatic cancer is complex and controversial because
pancreatic cancer itself can cause pancreatitis and hyperglycemia,
through destruction of the pancreatic parenchyma and other poorly
understood mechanisms 12.
CLINCIAL PRESENTATION
Because most pancreatic cancers arise in the right side of the
gland, the hallmark clinical presentation for periampullary and
pancreatic cancer is jaundice, resulting from obstruction of the
intrapancreatic portion of the common bile duct. The jaundice is often
8progressive and associated with dark urine, light stool, and pruritus.
Although some patients exhibit vague, intermittent epigastric pain,
locally advanced pancreatic cancer with tumor invasion of the celiac
plexus typically causes a constant dull epigastric pain, often
accompanied by back pain.
In 15% to 20% patients with pancreatic cancer, new-onset
diabetes mellitus is observed11 .  The suspicion of pancreatic carcinoma
should be raised in patients older than 60 years who develop mild
diabetes. Similarly, the possibility of a pancreatic neoplasm causing
partial pancreatic duct obstruction should be considered in elderly
patients with newly diagnosed pancreatitis, particularly in the absence of
cholelithiasis and ethanol abuse. Obstruction of the pancreatic duct also
may cause pancreatic exocrine insufficiency, manifested by
malabsorption and steatorrhea.
Nonspecific symptoms, such as nausea, anorexia, weight loss, and
fatigue, are common in many patients with periampullary cancer.
Obstruction of the C loop of the duodenum and at the ligament of Treitz
can develop as a result of local tumor involvement from the
periampullary region and midbody of the pancreas. On initial
presentation, jaundice is the most common physical finding. Evidence of
cutaneous scratching is commonly present, secondary to the pruritus.
9Patients with disseminated pancreatic cancer may exhibit left
supraclavicular adenopathy (Virchow’s node), ascites, palpable hepatic
metastases, periumbilical lymphadenopathy (Sister Mary Joseph’s
nodules), or drop metastases surrounding the perirectal region (Blumer’s
shelf).
Laboratory analysis often reveals elevated liver function studies,
reflecting the degree of biliary obstruction. Hyperglycemia is commonly
seen, but the mechanism for this is unclear. In deeply jaundiced patients
with malabsorption of fat-soluble vitamins, prolongation of the
prothrombin time may be seen.
Serum carbohydrate antigen 19-9 (CA 19-9) may be elevated;
however, this tumor marker is neither sensitive nor specific for
pancreatic cancer because 15% of patients do not secrete CA 19-9
owing to their Lewis antigen status. CA 19-9 levels may not be elevated
early in the disease. Using a cutoff of 37 U/ml, the sensitivity and
specificity for pancreatic ductal adenocarcinoma have been reported to
be 81% to 85% and 85% to 90% (Tamm et al, 2003). Levels greater
than 120U/ml have been predictive of metastatic disease (Cooperman,
2001). The main value of CA 19-9 is in follow up of patients after
curative resection and in monitoring their response to chemotherapy.
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DIAGNOSIS AND ASSESSMENT OF RESECTABILITY
Clinical staging should define the extent of disease reliably,
avoiding unnecessary intervention and the accompanying morbidity,
mortality and diminished quality of life in patients with advanced
disease13. Although the TNM staging system is used most often in
clinical trials, in practice physicians typically classify patients as having
resectable, locally unresectable and metastatic disease14. Resectable
pancreatic cancer is universally defined, based on preoperative workup,
as a pancreatic tumor without evidence of involvement of the superior
mesenteric artery or the celiac axis, a patent superior mesenteric-portal
venous confluence, and no evidence of distant metastasis15. Portal vein
involvement is controversial, and  resectability often depends on the
operating center. Imaging is the mainstay for diagnosing and staging
pancreatic tumors, in contrast to the traditional approach of surgical
exploration and a hands-on intraoperative examination to determine
resectability.
COMPUTED TOMOGRAPHY
Helical computed tomography (CT) has been established as the
most efficacious initial staging study 16and often is used as the entry
point to a management algorithm. The experience, cost, popularity, and
11
ease of interpretation favor helical CT as the most sensitive initial test to
diagnose and stage pancreatic cancer17.Multiplanar three-dimensional
reconstructions can provide  involvement of vascular structures and the
degree and level of dilation of the pancreatic and biliary ducts18.
Although the superior mesenteric vein is best seen with axial cuts,
sagittal reformatting is best for showing superior mesenteric artery
involvement19.  Coronal reformatting can show possible tumor extension
into the adjacent duodenum or stomach. Duodenal assessment is
enhanced further with the use of a negative oral contrast agent such as
water.
Regarding resectability, spiral CT scan has been reported to have
a positive predictive value of 100%, negative predictive value of 56%,
and overall accuracy of 70% for unresectable pancreactic carcinoma 19.
This ability to predict unresectability preoperatively is superior to the
ability to predict resecability, particularly because the detection of small
(<5mm) liver and peritoneal metastases is limited even with today’s CT
technology. Vascular involvement is the next most common reason for
unresectability. Tumor encasement is inferred from narrowing or
obliteration of vascular lumen, and radiologic grading criteria have been
developed for circumferential vessel involvement20,21. Generally if the
tumor surrounds more than half the circumference of a named vessel, it
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is deemed unresectable. Additional radiologic features that suggest
vascular invasion include perivascular cuffling, described as increased
attenuation of the normal perivascular fat, and the presence of dilated
collateral veins. The “teardrop” sign, which describes the deformity of
the otherwise round shape of the superior mesenteric vein, suggests
venous invasion22. An added bonus afforded by the excellent overview
of pertinent anatomy and structures is the use of the multidetector CT as
a valuable preoperative planning tool23.
MAGNETIC RESONANCE IMAGING & MRCP
Magnetic resonance imaging (MRI) has been compared
extensively with CT for the detection of vascular invasion and distant
metastases, and most studies have shown equivalent accuracy between
the two modalities24. MRCP offers a noninvasive delineation of the
pancreatic and biliary ducts. It detects pancreatic or ampullary
carcinoma by showing the effect of a space occupying lesion on the
ducts – obstruction or displacement. The classic feature is the “double-
duct” sign. Even a strictly defined double-duct sign is only 80% to 85%
specific for malignancy, however (Menges et al, 2000). Most recent
applications include secretin-enhanced MRCP, which can improve
pancreatic duct and side branch delineation. Such pharmacologic
stimulation of pancreatic juice secretion potentially can allow the
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evaluation of pancreatic flow dynamics and assessment of pancreatic
exocrine function19.
ENDOSCOPIC ULTRASOUND
EUS is more sensitive in detecting small lesion (<20 mm), with a
sensitivity of 93% to 100%. In a meta-analysis of studies comparing
staging by EUS with other modalities, EUS (without fine-needle
aspiration) more accurately predicted T stage, N stage, and portal vein
involvement than CT. One of the greatest attributes of EUS is the ability
to perform EUS-guided fine-needle aspiration of the primary tumor and
the regional lymph nodes without the risk of tumor seeding along the
needle tract, as opposed to the percutaneous route26. EUS guided fine-
needle aspiration is only of diagnostic value, however, if histology
confirms a pancreatic tumor. The major limitations of this technology
are operator dependence and a limited field of visualization for the
detection of distant metastasis.
ERCP
With the advent of MRCP, EUS, and multidetector CT with
multiplanar three-dimensional reconstruction, the role of endoscopic
retrograde cholangiopancreatography (ERCP) as a diagnostic tool is
becoming increasingly limited. Besides the everpresent risk of
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pancreatitis, the use of ERCP in an obstructed system might induce
cholangitis. A normal pancreatogram does not equate absence of
malignancy, and this can occur in approximately 20% of patients with
pancreatic cancer. Potential “blind spots’ on ERCP include the uncinate
process, the accessory duct, and the tail. In a study comparing ERCP
with MRCP in evaluating patients with suspected malignant bile duct
obstruction, it was found that the presence and site of the biliary stenosis
were assessed correctly in 100% of cases using MRCP, as opposed to
95% with ERCP27. MRI has an additional advantage given its ability to
provide cross-sectional anatomic evaluation of the upper abdomen.
POSITION EMISSION TOMOGRAPHY
Position Emission Tomography (PET) is being used to detect the
primary malignant tumor, to detect regional and distant metastases, to
differentiate benign disease from malignant disease or recurrent cancer
from treatment-related scarring, and to document response to therapy28.
In an extensive review of the FDG PET literature in the year 1993-2000,
the  overall  sensitivity  and  specificity  of  FDG  PET  as  an  oncologic
imaging tool were 84% and 86%, respectively.
FDG PET has been found to be more accurate than other imaging
methods in detecting pancreatic cancer. It is especially useful in
localizing the disease when CT is equivocal owing to treatment-related
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anatomic alteration29. PET provides an alternative in tumors less than 2
cm in diameter.
By changing the radiotracer to carbon 11-labeled 5-hydroxyl L-
tryptophan, PET imaging also has found a niche in the detection of
neuroendocrine tumors. 5-Hydroxyl-L-tryptophan PET has been
reported to fare better than CT and somatostatin receptor scintigraphy
for tumor visualization and has allowed the detection of many small,
previously overlooked lesions.
PET is not without pitfalls. False negative results have been
reported in patients with hyperglycemia and patients with very early
stage cancer or well-differentiated tumors. Because of limited spatial
resolution and the absence of anatomic landmarks, PET is inferior to CT
in assessing surgical resectability, in particular, vascular encasement. It
is believed that PET performed in isolation has only a limited role in the
workup of pancreatic cancer. The findings should be correlated with CT
scans to obtain complementary information. This need has led to the
development of hybrid PET-CT scanners, a combined physiologic and
anatomic diagnostic modality.
DIAGNOSTIC LAPAROSCOPY
Diagnostic laparoscopy was introduced as a minimally invasive
strategy for the detection of peritoneal carcinomatosis and liver
16
metastases to avoid unnecessary laparotomies in patients with advanced
disease. Used in conjunction with helical CT, laparoscopic assessment
can have a positive predictive value of 100%, a negative predictive
value  of  91%  and  an  overall  accuracy  of  94%30. Laparoscopic
ultrasound was added as an adjunct to laparoscopy to allow the detection
of intraparenchymal lesions and vascular invasion or encasement. With
ultrasound, the accuracy of determining resectability is improved to
98%. Advocates have reported that laparoscopy can identify occult
metastases, which were not detected by a preceding CT scan, in 30% of
patients. Consequently the resection rates after laparoscopy have been
reported to be 75% to 95%. Because of these results, some centres
strongly recommend the use of diagnose laparoscopy as a routine
procedure. But the same is not justified31 and laparoscopy is performed
for patients at high risk of occult metastatic disease and in whom a
palliative procedure is not required. In addition, laparoscopy can be
performed for patients with ascites, larger primary tumors, and whose
clinical or laboratory findings suggest an already advanced disease31.
STAGING
Currently, only a few patients with pancreatic cancer are
candidates for surgical resection, the only potentially curative therapy.
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In most patients, accurate preoperative staging of periampullary
and pancreatic cancer is achieved by multidetector CT with three-
dimensional reconstruction. A resectable tumor is characterized by no
evidence of metastatis disease, a clear tissue (fat) plane between the
tumor and the visceral arteries (celiac axis and superior mesenteric
artery), and less than or equal to 180-degree-circumferential
involvement of the superior mesenteric vein-portal vein confluence. In
contrast, patients with unresectable disease exhibit distant metastases,
ascites, involvement of the superior mesenteric artery or celiac axis, or
total occlusion of the superior mesenteric vein-portal vein confluence.
Using three-dimensional CT to stage patients who subsequently
underwent laparotomy for periampullary cancer, 98% of patients with
three-dimensional CT scans interpreted unequivocally as resectable
underwent resection. For patients with nondefinitive three-dimensional
CT criteria of unresectability (e.g., questionable superior mesenteric
artery involvement or near-complete superior mesenteric vein-portal
vein encasement with preserved patency), only 22% underwent
resection. Patients with nondefinitive radiographic criteria for
unresectability should not be committed to nonoperative therapy.
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TREATMENT
Surgical resection of periampullary and pancreatic cancer remains
the only potentially curative therapy. Only a few patients currently
diagnosed with pancreatic cancer are candidates for curative resection. It
is hoped that as early detection schemes improve and gain widespread
use, the percentage of patients who are candidates for resection will
increase. Approaches for resection are based on tumor location and
extent. Resection of right-sided tumors typically requires pancreatic-
oduodenectomy.
In many instances, preoperative biliary decompression is
unnecessary and may result in increased postoperative complications32.
Selected patients with biliary sepsis, advanced malnutrition, or
significant time delay before surgery may benefit from preoperative
biliary decompression, which can be accomplished endoscopically with
a plastic endoprosthesis in most instances. If endoscopic decompression
cannot be accomplished, placement of a percutaneous transhepatic
biliary drainage catheter can be pursued.
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PREOPERATIVE MANAGEMENT
Preoperative Workup and Preparation
General
Pancreatic resections exert a significant physiologic stress on
patients. Many patients are elderly (the peak incidence of pancreatic
cancer falls in the 65-75 year age group)33.  In such patients, there also is
a higher incidence of comorbidities.
Cardiopulmonary exercise testing and lung function testing has
been shown to examine accurately the ability of the cardiorespiratory
system to deliver oxygen under stress and the need for postoperative
ventilator support. Weight loss and dehydration are frequent features of
patients with pancreatic disease, and in such patients, the initial effort is
to maximize preload. Optimization of after load and myocardial
contractility is equally important, and occasionally pulmonary artery
catheters are inserted to facilitate this.
Before any major procedure involving resection, the patient’s
blood is matched for 2 units. Routine blood investigations and serum
tumor marker assay, specifically CA 19-9 are done.
Meta-analysis of the role of low molecular weight heparin in the
prevention of venous thromboembolic events in general surgery has
20
shown that low molecular weight heparin can reduce significantly the
incidences of asymptomatic deep vein thrombosis, clinical venous
thromboembolism, and pulmonary embolism with a trend toward a
reduction in overall mortality rate. Consequently, a prophylactic dose of
low molecular weight heparin to patients starting from the evening
before the day of surgery until the patients are ambulant postoperatively
is advised. In addition, patients are prescribed compression stockings,
which they wear intraoperatively and for their entire inpatient stay.
Stockings are believed to reduce pooling of blood in deep veins by
mechanically preventing venous distension and  are a simple,
inexpensive method of deep vein thrombosis prophylaxis.
Antibacterial prophylaxis has been instrumental in the reduction
of infection-related morbidity with clean contaminated procedures34, and
as such, it is recommended for all patients undergoing hepatobiliary or
pancreatic surgery. Drugs with antianaerobic activity are added if there
is an anticipated encounter with anaerobes during the procedure, in
particular, with procedures involving the gastrointestinal tract. The
general guideline is to use the highest licensed dosage of the chosen
antimicrobial agent. This agent should be administered at induction of
anesthesia to achieve high peak tissue concentration at the site of the
wound before the first incision and should be maintained until the time
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of closure. Redosing should be done when the procedure lasts more than
2 antibiotic half-lives. In all procedures in which the biliary tract is
entered, the bile is sent for microbiologic examination to guide
postoperative antimicrobial treatment should this need arise.
Pancreatic cancer is notorious in its association with significant
metabolic and nutritional disturbances. Weight loss of 10% or more is
well known to affect outcome adversely with an overall increased
susceptibility to postoperative complications. Clinical trials addressing
the role of preoperative nutritional therapy have found no reduction in
morbidity or mortality using either total parenteral nutrition (TPN) or
enteral nutrition. The controversy is fuelled further by the observation
that the surgical mortality or morbidity has decreased significantly
without emphasis on prior perioperative nutrition. Perhaps only patients
with severe malnutrition, in particular patients with physiologic
impairment, would have a tangible benefit from perioperative and
postoperative nutritional support35.
Patients in whom, for some reason, surgical extirpation has to be
delayed and have a demonstrable loss of weight, or patients with severe
malnutrition with physiologic dysfunction are candidates for nutritional
support. The latter group can be identified using physiologic function
tests, such as hand grip strength. Even lung function testing can serve as
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a simple assessment for voluntary muscle function. Serum markers, such
as transferin, peralbumin and retinol binding protein, also are invaluable
in confirming significant malnutrition. These are more accurate than
albumin as a marker of nutritional well-being. If perioperative
nutritional support is required, the enteral route is preferred.
ROLE OF SOMATOSTATIN
The pancreaticoenteric anastomosis is nicknamed the “Achilles
heel” of pancreaticoduodenectomy because of the potentially disastrous
sequelae of life-threatening intra-abdominal sepsis and haemorrhage in
the event of a pancreatic leak. Based on the findings of the trials
conducted by Buchler et al, 1992 &  Friess et al, 1995b  all patients
scheduled for pancreatic resections, were given a prophylactic
subcutaneous octreotide (Sandostatin), beginning with the first dose of
200 µg given at induction. If the pancreas is deemed to be high risk by
the surgeon, because of a soft consistency or a pancreatic duct size of
less than 3 mm in diameter, the postsurgical regimen would be three
daily doses of 200 µg of octreotide for the next 5 days. Conversely, if
the gland is firm with a relatively wide duct, each individual dosage
would be 100 µg.
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ROLE OF PREOPERATIVE BILIARY DRAINAGE
Patients with pancreatic cancer who have jaundice also are at risk
for associated coagulopathy, malabsorption, malnutrition, and immue
dysfunction. There have been at least two meta-analyses published on
this subject. Sewnath and colleagues (2002) found that there was no
difference in the overall death rate between patients who had PBD and
patients who had surgery without PBD38. Instead, the overall
complication rate was significantly adversely affected by PBD. The
length of hospital stay also was prolonged. The investigators concluded
that PBD carries no benefit. In a more recent review, Saleh and
associates (2002) found no evidence of either a beneficial or an adverse
effect of preoperative biliary stent placement on the outcome of surgery
in patients with pancreatic cancer39.  The  role  of  PBD  in  patients  with
biliary obstruction undergoing  pancreatic resection is controversial at
best. What is clear is that endoscopic drainage is better than
percutaneous methods. So preoperative biliary drainage, as a routine
practice, is not warranted rather than, it can be done for patients with
cholangitis or other severe complications of jaundice that would
preclude a safe resection. Another indication would be jaundiced
patients requiring induction therapy before surgical extirpation.
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EPIDURAL ANALGESIA
Studies on “fast track” gastrointestinal surgery have shown that
epidural analgesia, combined with an intensive and standardized
regimen of early feeding and mobilization, can reduce hospital stay40.
Epidural analgesia has been found to have many attributes, including a
shorter duration of postoperative ileus, attenuation of the stress
response, fewer pulmonary complications, improved postoperative pain
and mobility. Thoracic epidural analgesia is of particular benefit to
patients with a high risk of cardiac or pulmonary morbidity and is able
to reduce the hospital stay and costs in this subgroup of patients.
OPERATIVE MANAGEMENT
Panceraticoduodenectomy
Technique
The patient’s abdomen is cleansed from the nipple level down to
the level of the symphysis pubis, and the operative field is squared off
with sterile drapes. By either a midline or roof-top incision peritoneal
cavity is entered. The ligamentum teres and the adjoining falciform
ligament is routinely divided to facilitate a thorough examination of the
liver. The peritoneal surfaces also are inspected carefully for metastatic
deposits. Particular attention is paid to the pelvis for drop metastasis and
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the root of the mesenteric artery. Resection is proceeded only if there is
no evidence that would preclude an R0 resection.
Access into the lesser sac is achieved by division of the
gastrocolic ligament. On the left side, the gastrocolic ligament is divided
as far as the most medial branch of the short gastric vessels. This is to
ensure an alternative venous egress for the splenic blood flow in the
event of any venous resection of the superior mesenteric vein-portal
vein trunk. Moving toward the right, the hepatic flexure is mobilized
caudally. Careful dissection in the avascular plane between the hepatic
flexure and the duodenum and extension of the Kocher maneuver allows
the third part of the duodenum to be freed from the colonic mesentery.
The gastrocolic venous trunk of Henle is encountered here, and tracing
it down leads to the superior mesenteric vein. Alternatively, the superior
mesenteric vein can be identified through a Cattell Braasch maneuver.
The gastropiploic vein is divided where it empties into the gastrocolic
trunk. The superior mesenteric vein is traced to the inferior margin of
the pancreas. The peritoneum overlying the inferior border of the
pancreas is divided to allow better definition of the pancreatic margins.
Two stay sutures are placed at the inferior border of the pancreas to aid
in the creation of the tunnel between the pancreatic neck and the
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superior mesenteric vein-portal vein trunk. Attention is now turned to
the supraduodenal compartment.
Cholecystectomy is performed in a fundus-first approach. The
cystic  duct  is  traced  to  its  origin  from  the  common  bile  duct,  and  the
common bile duct is transected just cephalad to this point. Extreme care
is taken at this point to avoid any iatrogenic injury to the right hepatic
artery, which usually runs posterior to the hepatic duct41. The distal end
of the common bile duct and its adjoining fibrofatty tissues are dissected
free from the rest of the hepatoduodenal ligament and retracted caudally.
A small noncrushing clamp is applied to the proximal bile duct stump to
prevent any further bile spillage for the rest of the operation. The proper
hepatic artery is identified and looped. This is traced proximally toward
the common hepatic artery. The gastroduodenal artery can be isolated
during this dissection. Nodal tissues surrounding the proper hepatic
artery and the common hepatic artery are excised. The gastroduodenal
artery is divided near its origin. A potential pitfall here is the
misidentification of a replacing common hepatic artery or even a
replacing right hepatic artery as the gastroduodenal artery. A technique
to avoid this mistake is to place a vascular clamp across the presumed
gastroduodenal artery and checking for pulsations at the porta hepatis
before this vessel is divided. The stomach is then divided and retracted
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to the left upper quadrant of the abdomen. The suprapancreatic portion
of the portal vein is now widely exposed. Two stay sutures are similarly
placed on the superior border of the pancreas. These sutures at the
superior and inferior pancreatic borders also serve to ligate the superior
and inferior pancreatic vessels running longitudinally in the parenchyma
and reduce bleeding from the cut edges after transaction. Using peanut
swabs and blunt forceps, a tunnel is created cautiously between the
superior mesenteric vein-portal vein trunks posteriorly and the
pancreatic neck anteriorly. A silicon drain is insinuated into this tunnel
to loop up the neck.
The venous trunk is examined for any tumor involvement on its
posterolateral aspect. If venous resection is required, this is reserved as
the last step in the extirpative phase. The portal vein is gently retracted
medially to expose the underlying tissues, and any venous branches are
divided. At the same time, the specimen is retracted to the right. The
tissue and branch arteries arising from the superior mesenteric artery are
serially clamped, divided, and stitch ligated. During this step, the
specimen is cupped within the left hand of the surgeon, and the fingers
continuously appraise the position of the superior mesenteric artery to
avoid any injuries to it. The anterolateral aspect of the superior
mesenteric artery is completely skeletonized of its investing tissues. The
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third part of the duodenum is transected using a linear stapler, freeing
the entire specimen. Margins are harvested from the proximal pancreatic
stump and the bile duct for margin analysis by frozen section.
The ligament of Treitz is mobilized, and the mesenteric branches
to the fourth part of the duodenum are divided to allow it to be delivered
into the inframesocolic compartment under the superior mesenteric
artery. The pancreatic stump is rotated toward the left, and a collar of
investing tissue is cleared for a distance of 2 cm from the cut end to
provide a clear all-round visualization of the pancreatic capsule; this
facilitates the subsequent construction of the pancreaticoenteric
anastomosis. Hemostasis is ensured, and the operative field is washed
with warm water before proceeding to the reconstructive phase.
VASCULAR RESECTION:
 Fuhrman and co-workers (1996) found that tumors adherent to the
superior mesenteric vein – portal vein trunk did not exhibit more
aggressive biology, suggesting that venous adherence was a function of
tumor location rather than an indicator of aggressiveness. Subsequently,
studies have reported that the need for portal vein resection does not
affect overall patient survival. In 2004, new evidence emerged to
suggest that portal vein resection might confer some survival benefits. In
a prospective randomized study, Lygidakis and associates (2004)
29
showed that patients with portal-mesenteric venous invasion who were
randomized to venous resection had far better 2-year and 5-year
survivals compared with patients who were randomized to only
palliative bypass. Venous involvement can be described as short
segment  or  long  segment.  As  with  all  vascular  surgery,  proximal  and
distal control must be secured first. For short segment involvement, a
cuff resection is done. The strategy would be to dissect circumferentially
around the point of involvement to allow side clamping of the vein. The
involved area is excised with a longitudinal bielliptical incision with
clear margins, and the venotomy subsequently is closed in a transverse
fashion using nonabsorbable monofilament sutures in a continuous
fashion (Prolene 5-0). If a segmental resection is necessary to ensure
clear margins, reconstruction of the portal vein and superior mesenteric
vein can be accomplished in most instances by an end-to-end
anastomosis. Otherwise, a generous Cattell-Braacsh maneuver with or
without a caudal mobilization of the liver, usually would allow a
tension-free anastomosis, failing which a vein graft can be used.
LYMPHADENECTOMY:
 Several studies exist concerning extended lymph node dissection
and its potential benefits. Three level I studies hailed from centers from
three different continents – Europe42, North America (United States)43,44,
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and Asia (Japan)45. They all were unanimous in their verdicts – that
despite the increased radicality of lymphadenectomy, survival rates were
not prolonged. Ishikawa and colleagues (1997) provided a possible
explanation for these disappointing results. They found that patients
with lymph node metastases confined to the anterior and posterior
panceraticoduodenal groups fared as well as patients without any lymph
node involvement. In contrast, patients with involvement of other, more
distant lymph node groups did not benefit from an extended
lymphadenectomy (Ishikawa et al, 1997). A standard lymphadenectomy,
which would include the removal of the anterior and posterior
pancreaticoduodenal groups, would suffice.
MANAGEMENT OF PANCREATIC REMNANT:
The aftermath of a pancreatic leak can be devastating, particularly
when it results in retroperitoneal sepsis. This is found to be a major
cause of procedure-related mortality46. Simply occluding the duct has
been shown to result in higher fistula rates, in addition to increasing the
risk of pancreatic exocrine and endocrine insufficiency. Drainage of the
pancreatic remnant to the gastrointestinal tract is a crucial step, but it
runs the risk of anastomotic breakdown. The pancreaticoenteric
anastomosis has fascinated surgeons, motivating them to search for a
more reliable technique to avoid this dreaded complication. Many
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techniques have been described, and the literature will continue to report
novel techniques that promise to be even safer. Rather than the choice of
the variant used, however, the successful management of the pancreatic
anastomosis depends more on the surgeon’s concentration on the
meticulous execution of the technique with which he or she is familiar47.
As long as the basic tenets of a safe anastomosis are met, including
careful handling of the pancreatic tissues, a tension-free adaptation,
good perfusion, and no distal obstruction, any pancreaticoenteric
anastomotic technique can have a good outcome.
One of the most commonly employed technique is a pancreatic
ojejunal anastomosis. This anastomosis can be performed by
invaginating the transected pancreas into the end of the jejunum, the so-
called dunking procedure; another variant is to anastomose the
pancreatic duct directly to a proper opening in the jejunum, the so-called
duct-to-mucosa technique. The technique of pancreaticojejunal
anastomosis, whether end-to-side or end-to-end, and whether duct-to-
mucosa or dunking, does not seem to influence the anastomotic leak rate
significantly. Another strategy is to anastomose the pancreatic stump to
the stomach. Preponents of the pancreaticogastrostomy cite various
reasons48.  First, it is easier to perform, given the close proximity of the
stomach to the pancreas. Second, the anastomosis is less prone to
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ischemia because of the rich gastric perfusion. Third, because the
exocrine enzymes enter an acidic environment, the leak rate is
theoretically lower as the enzymes do not get activated. The last
statement has been debunked, however. In a prospective randomized
trial comparing pancreaticojejunostomy with pancreaticogastrostomy,
the leak rates were not significantly different (pancreaticojejunostomy
11%; pancreaticogastrostomy 12%)49.
In a prospective randomized trial50 of pancreaticogastrostomy
versus pancreaticojejunostomy after pancreaticoduodenectomy Yeo et al
has concluded that pancreatic fistula is a common complication after
pancreaticoduodenectomy, with an incidence most strongly associated
with surgical volume and underlying disease and the data do not support
the hypothesis that pancreaticogastrostomy is safer than
pancreaticojejunuostomy or is associated with a lower incidence of
pancreatic fistula. In a metaanalysis51 by Wente MN and Shrikande SV
et al they concluded that all non randomized observational clinical
studies have reported superiority of pancreaticogastrostomy over
pancreaticojejunostomy but all randomized controlled studies has shown
equally good results. In a study by H Ramesh et al results suggested that
pancreaticogastrostome deserves wider application52. In another
prospective randomized trial Bassi et al has showed that both type of
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anastamosis does not significantly change the risk of overall
complications or the incidence of pancreatic fistula. However,
significant decreases in the risk of associated complications, biliary
fistulas, postoperative collections and DGE were observed using
pancreaticogastrostomy. A Chinese metaanalysis53 of all four
randomized controlled trials has evidence suggesting that
pancreaticogastrostomy is better than pancreaticojejunostomy after
pancreaticoduodenectomy.
BILIARY-ENTERIC ANASTOMOSIS:
In contrast to the pnacreaticoenteric anastomosis, there are fewer
variations to the technique employed for the biliary-enteric anastomosis.
This anastomosis usually is constructed in an end-to-side fashion with a
single layer of sutures using monofilament absorbable sutures (PDS 5-0)
with C1 needle.
The anastomosis is positioned at about 20 to 30 cm downstream
from the pancreaticojejunostomy.
RECONSTITUTION OF GI CONTINUITY:
Depending on whether a distal gastrectomy or a PPPD was
performed, the reconstruction is done with a gastrojejunostomy (distal
gastrectomy) or a duodenojejunostomy (PPPD).
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Abdominal Drains and Nasogastric Tube. Intraperitoneal
drains have been placed in relation to the biliary and pancreatic
anastomosis with the intention of controlling leakage of blood or biliary,
lymphatic, or pancreatic secretions. This practice has been prophylactic
in nature, and it is based more on habit rather than evidence. This
practice has been challenged more recently. A randomized trial
addressing the value of drains after pancreatic resection found that
placement of drainsdid not translate into a reduction in surgical
morbidity54. Rather, a significantly higher proportion of patients
randomized to the drain group development intraperitoneal sepsis, fluid
collection, or fistula.
RESULTS
After resection of periampullary and pancreatic cancer, longterm
survival  is  determined  largely  by  the  site  of  tumor  origin.  In  an
evaluation 242 patients with resected periampullary adenocarcinoma at
the Johns Hopkins Hospital, the 5-year actual survival rate for the entire
cohort was 20%55. Actual 5-year survival rates were the best for
duodenal adenocarcinoma (59%) compared with the rest: ampullary
(39%), distal bile duct (27%) and pancreas (15%). For the entire group
of patients surviving 5 or more years, there were statistically more
duodenal and ampullary primaries, fewer node-positive resections,
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fewer margin-positive resections, and more well differentiated tumors
compared with patients who failed to survive 5 years.
In an analysis of 616 patients with resected adenocarcinoma of
the pancreas at the Johns Hopkins Hospital, several factors were found
to influence long-term survival56 shows that lymph node involvement,
margin positivity; tumor size greater than or equal to 3 cm, and poor
tumor differentiation all resulted in worse survival. Although there is
some controversy over whether patients do worse with pancreatic
adenocarcinoma arising from the left side versus the right side of the
gland, for patients who undergo resection, there seems to be no
statistical difference in survival. By multivariate analyses, pathologic
factors identified as prognostically favorably affecting outcome were,
negative resection margin,  tumor diameter  less than 3 cm, and good to
moderate tumor differentiation. Particularly for pancreatic primaries, an
important observation is that the survival rate continues to decline after
5 years, mostly owing to recurrent disease; 5-year survival does not
indicate a cure of pancreatic cancer, although the decrement in survival
beyond 5 years is less steep than the decrement in survival from the time
of surgery to 5 years postoperatively.
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ADJUVANT THERAPY : POSTOPERATIVE
CHEMORADIATION AND CHEMOTHERAPY
Overall, the 5-year survival for all patients diagnosed with
pancreatic cancer is only 3%. After resection, approximately15% to
20% of patients can be expected to survive 5 years, with most dying as a
result of recurrent disease, manifesting locoregionally and distantly.
These patterns of disease recurrence and general poor outcome support
the rationale for adjuvant chemoradiation. The first randomized
controlled trial evaluating adjuvant therapy for pancreatic cancer was
reported  by  the  Gastrointestinal  Tumor  Study  Group  (GITSG).  A
survival benefit was seen in patients randomly assigned to radiation
therapy combined with 5-fluorouracil (5-FU) compared with surgery
alone (median survival 20 months versus 11 months). Despite limited
accrual,  the  GITSG  trial  was  the  first  to  show  a  potential  benefit  for
adjuvant therapy after the first to show a potential benefit for adjuvant
therapy after resection of pancreatic cancer. Subsequent reports from the
GITSG and single institutions supported the use of adjuvant chemo
radiation. A randomized controlled trial conducted by the European
Organization for Research and Treatment of Cancer showed a trend
toward improved survival with adjuvant 5-FU-based chemo radiation
compared with surgery along in patients with periampullary and
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pancreatic cancer (Klinkenbijl et al, 1999); however, this study was
statistically underpowered and reported as a negative trial.
The results of the European Study Group for Pancreatic Cancer
(ESPAC-1) trial were reported by Neoptolemos and colleagues (2004).
Compared with the observation group, however, patients who received
chemoradiation alone seemed to have a worse median survival,
suggesting a possible role for treatment-related toxic radiation effects.
Although controversy surrounds the use of adjuvant
chemoradiation, several on-going clinical trials are exploring various
regimens.
NEOADJUVANT THERAPY
In theory, there are several potential advantages of therapy
administered in the neoadjuvant (preoperative) versus the post operative
adjuvant setting. In a series of 132 patients with resectable pancreatic
cancer at the M.D. Anderson Cancer Center, the investigators reported
that various neoadjuvant chemoradiation regimens followed by
pancreaticoduo- denectomy can be completed successfully with a
median survival of 21 months. Currently, there is no proven survival
benefit of neoadjuvant chemoradiation compared with postoperative
therapy; however, numerous trials are ongoing.
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MATERIALS AND METHODS
All patients attending the outpatient department of Surgical
Gastroenterology, Rajiv Gandhi Government General hospital between
August 2009 to December 2011 with symptoms and signs of obstructive
jaundice were evaluated by imaging studies and those patients found to
have distal obstruction due to malignancy were segregated.
All data were collected prospectively and the clinical parameters
were noted in a proforma. Besides age and gender, the chief complaints,
co-morbid illness, nature of diet, habit of smoking and alcohol
consumption were also noted. Findings on Physical examination such as
jaundice, pallor, pedal edema and other signs of liver failure if present
were noted. Clinical examination of the abdomen done to look for a
palpable gallbladder, hepatomegaly and free fluid. All patients were
subjected to a per rectal examination to rule out any possibility of rectal
deposits. All basic biochemical investigations including a complete
blood count, Renal function tests and Liver function tests were noted.
Coagulation profile and serum tumour marker study was done for all
patients. After an initial ultrasonogram of abdomen an upper GI
endoscopy and contrast enhanced computerised tomography was done
for all patients.
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Fifty patients with operable growth in the pancreatic head,
ampullary, distal bileduct and duodenum in the periampullary region
were included in the study group. Informed consent was obtained from
all the patients explaining the nature of illness and the magnitude of
morbidity and mortality. Whenever possible if a growth is seen at
endoscopy or side viewing scopy a biopsy was attempted. We do not
call  for  an  MRI  routinely,  but  if  a  patient  comes  with  an  MRI  and  the
information needed to assess the resectability is sufficient we don’t call
for CECT abdomen. The performance status of the patient is assessed
and the cardiorespiratory status evaluated. Hydration status, nutritional
status and coagulation profile are noted and corrected if necessary with
injection vitamin K and fresh frozen plasma. All patients were
encouraged to have incentive spirometry  for 2 weeks before surgery.
For patients with bilirubin more than 20mg% ,  poor performance status,
poor nutritional status and for those presenting with cholangitis a pre-
operative endoscopic biliary drainage was performed except for one
patient for whom we have performed an operative biliodigestive bypass
before pancreaticoduodenectomy.
All patients in the study were subjected for a standard whipple’s
pancreaticoduodenectomy. With the patient in supine position abdomen
is opened by a rooftop incision and thorough laparotomy done. After
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ascertaining the operability once more resection is proceeded. In the
process of reconstruction pancreaticoenteric anastamosis is done either
as a pancreaticogastrostomy or pancreaticojejunostomy as per the choice
of operating surgeon. Pancreaticogastrostomy is done usually by the
invaginating(dunking) technique in two layers. Pancreaticojejunostomy
is  done  as  an  end  to  side  anastomosis  by  Buchler’s  technique.
Hepaticojejunostomy is done using 3-0 vicryl interrupted sutures by
parachute technique. An antecolic gastrojejunostomy is done in either
cases. The duration of surgery, blood loss, number of transfusions, the
technique of pancreaticoenteric, bilioenteric and gastrojejunal
anastomosis were noted.
The day of removal of nasogastric tube, drainage tube and urinary
catheter in the post-operative period were noted. The values of serum
amylase and drainage tube amylase were noted on the 3rd and  if
necessary on the 5th postoperative day. A complete blood count and
Liver function tests were obtained at the time of discharge. The length
of postoperative stay was noted along with major complications like
delayed gastric emptying, early and late haemorrhage, pancreatic leak,
intra-abdominal collection and other minor complications like wound
infection, pneumonitis and urinary tract infection.
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The complications after whipple’s operation as noted in the
proforma were defined as follows:
Delayed Gastric Emptying
All  patients  who  were  unable  to  start  oral  fluids  by  7th day and
those who required ryles tube for more than 10 days or who required
reinsertion after 10 days were considered to have delayed gastric
emptying.
Haemorrhage
Bleeding complication following pancreaticoduodenectomy
requiring monitoring, transfusion, radiological and surgical intervention
were noted. Early haemorrhage occur within 24 hrs and late
haemorrhage occurred after 24 hrs.
Pancreatic leak
Any measurable amount of fluid after day 3 in the drainage tube
with amylase level more than 3 times that of serum values is suggestive
of pancreatic leak and has been graded A,B & C according to the
severity and plan of management.
Intra-abdominal collection
Any collection detected by ultrasonogram or CECT of more than
5 cm is noted as intra abdominal collection and planned for
percutaneous drainage.
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Wound infection
Any collection of pus or fluid at the operated site with mild fever,
leucocytosis and local inflammatory signs in the absence of any major
complications is defined as wound infection. It was managed by letting
out the pus or fluid, sending it for culture and sensitivity treating with
appropriate antibiotics.
Pneumonitis
Any post-operative lung signs with fever and diminished air entry
is defined as basal pneumonitis and aggressively treated by ambulation,
chest physiotherapy, antibiotics and nasal oxygen.
Urinary Tract Infection
Patients presented with fever with no other sources and positive
urinary culture. Treated by hydration, antibiotics and adequate glycemic
control.
STATISTICAL ANALYSIS:
The data collected in the proforma were entered in an excel sheet
of Microsoft Office software and inference obtained after statistical
analysis. The mean and standard deviation were reported for continuous
variables and for categorical variables proportions were computed. To
compare and find the statistical significance between the two group
proportions chi-square test was used and to compare between the two
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group means independent t-test was used. The P-values <0.05 were
considered to indicate statistical significance. All analyses were
performed by using SPSS version 16.0.
CECT ABDOMEN SHOWING A PERIAMPULLARY LESION
CHOLESTATIC LIVER WITH DISTENDED GALLBLADDER
KOCHERISATION
GASTRODUODENAL ARTERY LIGATION
CBD
HEPATIC
ARTERY
GDA
LIGATED
PORTAL
VEIN
PANCREATIC REMNANT
PANCREATICOGASTROSTOMY SEEN THROUGH AN
ANTERIOR GASTROTOMY
AFTER COMPLETION OF PANCREATICOGASTROSTOMY
HEPATICOJEJUNOSTOMY
GASTROJEJUNOSTOMY
RESECTED SPECIMEN
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RESULTS
Among the fifty patients included in the study 62% were male and
38% were female patients. The minimum age was 30 and maximum age
was 72 with a mean age of 51.7 and a standard deviation of 10.9.
On clinical presentation 90% had jaundice, 86% had abdominal
pain, 84% had weight loss, 56% had pruritus, 12% had fever, 14% had
cholangitis and 28% had other symptoms such as nausea, vomiting, loss
of appetite and constipation.
SYMPTOMATOLOGY
Symptoms Frequency Percent
JAUNDICE 45 90
ABDOMINAL PAIN 43 86
WEIGHT LOSS 42 84
PRURITUS 28 56
CHOLANGITIS 7 14
FEVER 6 12
OTHERS 14 28
On evaluating the patients for co-morbid illness 24% had
Diabetes Mellitus, 10% had hypertension 2% had bronchial asthma and
22% had previous surgery.
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CO-MORBID ILLNESS & PREVIOUS SURGERY
Co-morbid illness Frequency Percent
DIABETES MELLITUS 12 21
HYPERTENSION 5 10
BRONCHIAL ASTHMA 1 2
PREVIOUS SURGERY 11 22
Regarding the dietary habits 60% were non-vegetarians, 40%
were vegetarians, 32% were smokers and 48% were ethanol users.
CLINICAL EXAMINATION
Findings Frequency Percent
ICTERUS 41 82
PALLOR 10 20
PALPABLE GALLBLADDER 39 78
PALPABLE LIVER 20 40
On examination, 82% were icteric and 20% were in pallor.
Gallbladder was palpable in 78% of patients and liver was palpable in
40% of patients. Liver echoes were found to be normal in 92% of
patients. Intrahepatic biliary radical dilatation was found in 98% and
Common bileduct was dilated in 92% of the patients.
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ULTRASONOGRAM FINDINGS
Parameters Frequency Percent
LIVER ECHOES 46 92
IHBR DILATATION 49 98
CBD DILATATION 46 92
MASS VISUALIZED 17 34
Ultrasonogram was able to diagnose the mass only in 34% of the
patients. Vascular involvement was pre-operatively diagnosed in 1
patient and underwent resection. MRI scan was done in 24% of patients.
Biopsy was attempted in 86% of patients and pre-operative biliary
drainage was done in 18% of patients.
PREOPERATIVE BIOPSY AND BILIARY DRAINAGE
Procedure Frequency Percent
BIOPSY DONE 43 86
PREOP BILIARY
DRAINAGE
9 18
Among the study population the distribution of disease were as
follows: periampullary 82%, pancreatic 14%, distal CBD 2% and
duodenal growth 2%.
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Among the fifty patients, patients with one morbidity condition
were 14%, with two conditions were 12%, with three conditions were
14% and 60% had no morbidity. Among the complications delayed
gastric  emptying  occurred  in    18%,   haemorrhage  in  8%,  pancreatic
leak in 36 %( grade A-10%, grade B-16%, and grade C-10%), intra-
abdominal collection in 18%, wound infection in 24%, pneumonitis in
6%, urinary tract infection in 8% of patients. At the time of discharge
about 82% had a normal blood count and 90% had a normal liver
function tests.
DISTRIBUTION OF CLINICAL VARIABLES(BOTH PG & PJ GROUP)
N Minimum Maximum Mean Std.Deviation
Age 50 30 72 51.74 10.885
Hb 50 4.7 14.2 9.800 2.0562
TC 50 880 18000 6361.40 3458.263
P 50 45 90 69.98 9.410
L 50 7 42 24.78 8.112
E 50 1 10 4.80 2.433
ESR 50 10 156 61.40 33.879
TB 50 0 29 15.77 7.221
DB 50 0 21 11.43 5.743
SAP 50 72 720 304.82 179.350
Albumin 50 2.2 5.4 3.256 .4978
PT 50 10 20 13.56 2.201
INR 50 .80 1.64 1.1222 .18792
CA19-9 50 12.0 235.9 49.324 40.7025
Dur_surgery 50 4 11 5.96 1.568
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Blood_loss 50 80 4650 402.80 671.881
Transfusion 50 0 7 .78 1.529
RT_removal 50 0 16 7.61 3.328
Urinary 50 0 12 6.47 2.873
DT_removal 50 0 20 9.61 4.056
Serum_amylase 50 0 620 59.90 87.813
DT_amylase 50 0 8297 284.51 1181.301
Valid N
(listwise) 50
INTRAOPERATIVE VARIABLES (PG Vs PJ)
Technique N Mean Std.Deviation P-value
Dur_surgery
PG 24 6.15 1.931 0.426
PJ 26 5.79 1.150
Blood_loss
PG 24 550.00 915.091 0.138
PJ 26 266.92 272.746
Transfusion
PG 24 1.04 1.732 0.249
PJ 26 .54 1.303
POSTOPERATIVE EVENTS (PG Vs PJ)
T-Test Technique N Mean Std.Deviation P-value
RT_removal
PG 24 7.50 3.388 0.777
PJ 26 7.77 3.278
Urinary
PG 24 6.25 2.592 0.557
PJ 26 6.73 3.106
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DT_removal
PG 24 9.33 3.784 0.609
PJ 26 9.92 4.279
Serum_amylase
PG 24 68.58 120.673 0.469
PJ 26 50.50 35.991
DT_amylase
PG 24 418.54 1680.270 0.426
PJ 26 151.69 220.243
Post_stay
PG 24 12.58 4.624 0.710
PJ 26 13.08 4.681
When comparing between the two groups undergoing
pancreaticogastrostomy and pancreaticojejunostomy the incidence of
delayed gastric emptying in the PG group was 20.8% and the incidence
in the PJ group was 15.4%, the incidence of haemorrhage was 8.3% in
the PG group and 7.7% in the PJ group. When comparing the incidence
of leak between the two groups it was about 41.7% in the PG and 30.8%
in the PJ group. The incidence of intra abdominal collection in the PG
group was 12.5% and in the PJ group it was 23.1%. Regarding the
incidence of minor morbidities, the incidence of wound infection was
20.8% in the PG and 26.9% in the PJ group. There was no incidence of
pneumonitis in the PG group compared to 11.5% in the PJ group. The
incidence of urinary tract infection in the PG group was 8.3% and in the
PJ group it was 7.7%.  The mean duration of nasogastric tube removal
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was 7.5 days in the PG group and 7.8 days in the PJ group and the mean
days of urinary catheter removal was 6.3 days in the PG and 6.7 in the
PJ group. The mean days of drainage tube removal was 9.3 days in the
PG and 9.9 days in the PJ group. The mean postoperative hospital stay
was 12.6 days in the PG group and 13.1 days in the PJ group.
The mortality in the patients who underwent
pancreaticogastrostomy was 8.3% and the mortality in the
pancreaticojejunostomy group was 7.7%.The overall mortality rate was
8%.
MORTALITY (PG Vs PJ)
Mortality
TotalDied Alive
Technique PG Count 2 22 24
% within Technique 8.3% 91.7% 100.0%
PJ Count 2 24 26
% within Technique 7.7% 92.3% 100.0%
Total Count 4 46 50
% within Technique 8.0% 92.0% 100.0%
P=1.000
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DISCUSSION
Although the concept of cure after a curative
pancreaticoduodenectomy has been challenged, surgical resection is the
only therapy for all pancreatic head malignancies and periampullary
growth that gives the patient a significantly increased survival. Though
the mortality ranges between 3-5%, the morbidity following
pancreaticoduodenectomy is still in the range of 40-60%.  Morbidity and
mortality arising out of such a major surgical intervention requires
special attention for those with limited survival (10-30% are true 5 year
survivors). Hence analyzing the peri-operative factors influencing the
morbidity and mortality is important for a better outcome following this
procedure. In our study we have evaluated the perioperative variables
which influence the outcome between pancreaticogastrostomy and
pancreaticojejunostomy following whipple’s procedure.
Age & sex
As per various studies the peak incidence of pancreatic cancer is in the
60’s and 70’s and the mean age at diagnosis is 60-65 years11. There is a
slightly higher incidence in men than in women (relative risk 1.35) and
advancing age is perhaps the stronger risk factor. In our study the
minimum age at diagnosis was 30 and the maximum age was at 72. The
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mean age of presentation was 51.74 with a standard deviation of 10.9.
Out of the 50 patients 31(62%) were male and 19(38%) were female
patients. The difference was mainly due to inclusion of all periampullary
tumours taken for our study.
Clinical presentation
The hallmark presentation for periampullary and pancreatic
cancer is jaundice, resulting from obstruction of the intrapancreatic
portion of the common bile duct1 .  Although some patients exhibit a
vague abdominal pain, locally advanced pancreatic cancer with tumour
invasion of celiac plexus typically causes a constant dull pain
accompanied by back pain.non-specific symptoms such as nausea,
anorexia, weight loss and fatigue are common in many patients. Weight
loss of 10% or more is well known to affect outcome adversely with an
overall increased susceptibility to postoperative complications. In our
study 90% of patients presented with jaundice and 86% presented with
abdominal pain. 84% presented with weight loss, 56% presented with
pruritus, 12% with fever and 14% with cholangitis. Other symptoms like
nausea, vomiting, loss of appetite and fatigue were present in 28% of
patients.  Patients  with  cholangitis  and  poor  performance  status  were
subjected to endoscopic biliary drainage. All the 7 patients with
cholangitis were managed initially by endoscopic biliary drainage. One
53
of the patient who presented with cholangitis with performance status
ECOG 3  as  we  were  are  not  possible  to  drain  either  endoscopically  or
percutaneously we offered an operative biliodigestive bypass and
resected subsequently.
Nutritional status and co-morbid illness
Lillemoe et al observed that 15-20% patients with pancreatic
cancer had new-onset diabetes mellitus11 . As many patients are elderly33
there is also a higher incidence of co-morbid illness. Cardio-pulmanory
testing assess the ability to deliver oxygen during stress and the need for
postoperative ventilator support. Weight loss and dehydration are
frequent features in such patients and hence need to be aggressively
addressed. In our study diabetes mellitus was the major co-morbid
illness with an incidence of 24%, hypertension 10%, bronchial asthma
2% and 22% had previous surgery particularly in the female population.
Out of the 4 patients with mortality 2 of the patients had hypertension
and all the 4 patients had diabetes mellitus. So routine preoperative
blood tests and careful history taking might help surgeons to identify
high risk patients and subject them for optimization before such major
surgical procedure. All patients with previous surgery were females and
9 out of the 11 patients had undergone puerperal sterilisation. Previous
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surgery did not have any impact in the duration of surgery when
compared with patients who had no previous operation.
Personal habits
Though dietery habits have no direct influence, they have indirect
influence in the form of nutrirional status and hence the performance
status. 60% of patients were non-vegetarians and 40% were vegetarians.
This dietery habit had no influence on the outcome. The study had 32%
smokers and 48% alcoholic. Patients who were found to be nutritionally
depleted were encouraged to take adequate enteral formulas and
albumin infusion was administered  preoperatively.Patients with
significant morbidity related to pulmonary mechanism were all smokers.
Hence abstinence of smoking for atleast 2 weeks before surgery,
incentive spirometry, lung function tests, nebulisation with
bronchodilators and mucolytics,  aggressive postoperative chest
physiotherapy and ventilator support is given to all smokers. Among the
patients with mortality only one was a smoker. So although smoking has
an influence of postoperative chest infections and wound complications
as such it has no influence on the mortality.
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Physical examination
Jaundice was the most common clinical presentation with 82% and 20%
were anaemic. Gall bladder was palpable in 78% of the patients and
liver was palpable in 40%.
Imaging, endoscopy and biopsy
All patients underwent initial ultrasonogram of the abdomen and pelvis.
Liver  was  found  to  have  normal  echoes  in  92%  of  patients  with
intrahepatic biliary radical dilatation in 98% of study group. Common
bile duct dilatation was diagnosed in 92% of patients, wheras mass in
the head of pancreas or periampullary region was diagnosed only in
34% of patients. Therefore the accuracy of ultrasonogram in detecting
IHBR dilatation is more than that of CBD dilatation which in turn is
more than the presence of mass. Hence ultrasonogram is an easily
available, cost effective, less time consuming and adequate initial
imaging study to differentiate between proximal and distal biliary
obstruction but the disadvantage is the observer variation which is
operator dependent.
There are lot of evidence in literature that helical CT is the most
efficacious initial imaging study16 and is the most sensitive initial tool to
diagnose and stage pancreatic cancer17.Initially  we  did  CECT  for
evaluating but now we use 64 slice MDCT with vascular reconstruction
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for all patients to assess the resectablity with accuracy18. Those patients
deemed to be unresectable by distant metastasis, peritoneal metastasis
and vascular invasion were not included in the study except for one
patient with solid and cystic components of head of pancreas with portal
vein involvement for which we have done a pancreaticoduodenectomy
and vascular resection with grafting.
We have done upper GI endoscopy for all patients and attempted
for a biopsy if feasible with a side viewing scopy. If clinical,
biochemical and imaging modalities suggest distal obstruction and
operable growth we proceed with surgery even if the biopsy turns out to
be negative or inconclusive after explaining to the patient and the
relatives of the possibility of a benign postoperative biopsy report. Out
of the 50 patients 43 patients were biopsied and all the preoperative
biopsies correlated with postoperative biopsy reports.
Preoperative biliary drainage
There are 6 prospective randomized studies(Hattfield et al
1982,Mc person et al 1984, Smith et al 1985, Smith etal, Lai et al, Wig
et al) which analysed the outcome after a preoperative biliary drainage.
Only 2 studies suggested that preoperative biliary drainage is beneficial
(Smith et al & Wig et al). A meta-analysis by Sewnath has showed that
routine preoperative biliary drainage carries no benefit38. Instead there is
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a high complication rate with prolonged hospital stay. Saleh and his
associates have showed that there is no evidence of either a beneficial or
an adverse effect of preoperative biliary stenting. We have done
preoperative biliary drainage for 9 patients(18%). Majority of the
indications were for cholangitis and the rest for poor performance status
with biliribin more than 20. One patient underwent open surgical
biliodigestive bypass for poor nutritional status with vomiting with
ECOG3 and later proceeded with resection.
Provisional diagnosis
The distribution of diseases in our study as follows:
Periampullary40 (80%), head of pancreas 6(12%), duodenal 2 (4%) and
distal bileduct 2(4%).
Biochemical parameters
The mean haemoglobin concentration was 9.8 with lowest at 4.7
and highest at 14.2 and the need for preoperative transfusion is decided
when haemoglobin is less than 8g%.The mean total count was 6361.4
and the highest was 18000 which is a clue to diagnose cholangitis earlier
and hence decide upon urgent endoscopic biliary decompression. The
mean bilirubin value is 15.8mg%  as literature evidence suggests
malignancy with a level above 10mg%. The mean serum alkaline
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phosphatase value was 304.8. Serum albumin was from 2.2 – 5.4 and
the average value is 3.25g%.
Intraoperative factors
The mean duration of surgery was 5.9 hours with shortest
duration of 4 hours and longest duration of 11 hours. This patient had a
portalvein resection with artificial venous graft. The mean blood loss
was 402.8 ml and on an average blood requirement was 0.78 bottles per
patient. There was slightly more blood loss in the
pancreaticogastrostomy group than pancreaticojejunostomy group.
Type of anastomosis
Among the 50 patients 24underwent pancreaticogastrostomy and
26 underwent pancreaticojejunostomy. On analyzing the preoperative
variables among both the sub-groups they were almost comparable with
each other. Though there were minor difference they were not
statistically significant. There are 4 randomized controlled trials, 1
favouring pancreaticogastrotomy in terms of lesser leak rate (Fernandez
cruz L et al,2008). 3 RCT’s (Bassi et al, Yeo et al & Duffas et al) have
showed PG and PJ to be similar in terms of leak rate. 1 meta-analysis by
Mc Kay et al has favoured PG and other meta-analysis by Wente et al
has shown no difference between both subgroups in terms of leak as
well as major morbidity. Though there is a prolonged operative time
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(mean 6.15 hours) in the PG group when compared with the PJ group
(5.79 hours) it is not significant statistically (P value=0.426). As our
centre is a teaching institution where surgery is done by Professors,
Assistant Professors and Post Graduates there is a wide variation in the
duration of surgery and hence the morbidity. The amount of estimated
blood loss in PG group was 550 ml and in the PJ group was 267 ml
which is not statistically significant (P value=0.138) though there is an
apparent difference. Comparing between both the subgroups there was
no significant difference in terms of removal of nasogastric tube,
drainage tube and postoperative stay. Even the biochemical
investigation reports at the time of discharge showed no significant
statistical difference between the two subgroups.
The incidence of haemorrhage was 8.3% (2) in the PG and 7.7%
(2) in the PJ group. The difference is not statistically significant as the P
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value is 1.000. Two patients were managed by endoscopically and two
patients were managed conservatively. The incidence of pancreatic leak
were higher in the PG group when compared to the PJ group. But the
trend in the incidence of leak indicates that there were more leaks in the
initial half of study than in the later half which helps in concluding a
possibility of a learning curve in the process of pancreatic remnant
anastomosis. The incidence of intra-abdominal collection was 12.5% in
the PG group compared to 23.1% in the PJ group. Though the incidence
is less in the PG group, it is not statistically significant (P value=0.467).
The incidence of wound infection in the PG group was 20.8% (5) and in
the PJ group it was 26.9%(7). No patient developed pneumonitis in the
PG group but 3 patients had in the PJ group which is again not
significant statistically. 8.3% developed urinary tract infection in the PG
and 7.7% in the PJ group.
DELAYED GASTRIC EMPTYING (PG Vs PJ)
Technique * DGE
DGE
Total
Yes No
Technique
PG
Count 5 19 24
% within Technique 20.8% 79.2% 100.0%
PJ
Count 4 22 26
% within Technique 15.4% 84.6% 100.0%
Total
Count 9 41 50
% within Technique 18.0% 82.0% 100.0%
P=0.721 not significant
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HAEMORRHAGIC COMPLICATION (PG Vs PJ)
Haemorrhage
TotalYes No
Technique PG Count 2 22 24
% within Technique 8.3% 91.7% 100.0%
PJ Count 2 24 26
% within Technique 7.7% 92.3% 100.0%
Total Count 4 46 50
% within Technique 8.0% 92.0% 100.0%
P=1.000
PANCREATIC LEAK(PG Vs PJ)
PANCREATIC LEAK
TotalA B C No leak
Technique PG Count 4 3 3 14 24
% within Technique 16.7% 12.5% 12.5% 58.3% 100.0%
PJ Count 1 5 2 18 26
% within Technique 3.8% 19.2% 7.7% 69.2% 100.0%
Total Count 5 8 5 32 50
% within Technique 10.0% 16.0% 10.0% 64.0% 100.0%
P=0.403
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Morbidity
Among the 50 patients 7 patients developed delayed gastric
emptying, 6 patients developed DGE and pancreatic leak and 7 patients
developed other complications along with DGE and pancreatic leak
accounting for a morbidity of 40%. The incidence of delayed gastric
emptying in the PG group was 20.8%(5) when compared to PJ group
which was 15.4%(4). The maximum days we have retained the
nasogastric tube was for 16 days. We have managed the patients with
prokinetics and maintaining them on enteral feeding through feeding
jejunostomy. Though there is an apparent difference among both the
groups there is no statistical difference (P value=0.721). Pancreatic leak
occurred in 18 patients with grade A leak in 5(10%), grade B leak in
8(16%) and grade C leak in 5(10%) patients. All patients with
pancreatic leak were managed by non-operative means. Grade A leaks
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were managed conservatively and grade B leaks required supportive
care in the postoperative ward with drainage tube retained for a
prolonged period and grade C leaks were managed aggressively in the
ICU with one or more image guided percutaneous drainage tubes and
nutritional support. We have not reoperated for a suspected leak.
Similarly there is no statistically significant difference in the outcome
between pancreaticogastrostomy and pancreaticojejunostomy in terms
of other major morbidities.
INRA-ABDOMINAL COLLECTION (PG Vs PJ)
Intra_abd_coll
TotalYes No
Technique PG Count 3 21 24
% within Technique 12.5% 87.5% 100.0%
PJ Count 6 20 26
% within Technique 23.1% 76.9% 100.0%
Total Count 9 41 50
% within Technique 18.0% 82.0% 100.0%
P=0.467
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WOUND INFECTION (PG Vs PJ)
Wound infection
TotalYes No
Technique PG Count 5 19 24
% within Technique 20.8% 79.2% 100.0%
PJ Count 7 19 26
% within Technique 26.9% 73.1% 100.0%
Total Count 12 38 50
% within Technique 24.0% 76.0% 100.0%
P=0.745
PNEUMONITIS (PG Vs PJ)
Pneumonitis
TotalYes No
Technique PG Count 0 24 24
% within Technique .0% 100.0% 100.0%
PJ Count 3 23 26
% within Technique 11.5% 88.5% 100.0%
Total Count 3 47 50
% within Technique 6.0% 94.0% 100.0%
P=0.236
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URINARY TRACT INFECTION (PG Vs PJ)
UTI
TotalYes No
Technique PG Count 2 22 24
% within Technique 8.3% 91.7% 100.0%
PJ Count 2 24 26
% within Technique 7.7% 92.3% 100.0%
Total Count 4 46 50
% within Technique 8.0% 92.0% 100.0%
P=1.000
Mortality
The mortality rate in our study was 8% (8.3% in PG group and 7.7% in
PJ group) which is again statistically not significant (P value=1.000)
between the two groups. The mortality rate in the literature is in the
range  of  3-5%.  In  our  study  the  reason  for  mortality  were  due  to
cardirespiratory impairment due to myocardial infarction and other two
cases were due to haemorrhage and metabolic encephalopathy. One of
the patient had an urgent endoscopy and we could not find any bleeding
points except for clots. Patient was on ventilator with haemodynamic
support and could not be shifted for angioembolisation. We reopened
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and explored but could not find the source and patient succumbed with
multiorgan failure. The other patient was haemodynamically unstable on
day 4 and before we could intervene patient succumbed due to
metabolic encephalopathy. Both the patients had adequately controllable
co-morbid illnesses. Though our study showed a 41.7% leak in the PG
group and 30.8% in the PJ group all the patients were managed
successfully and no patients with leak had mortality.
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CONCLUSION
There is no statistically significant difference in outcome between
pancreaticogastrostomy and pancreaticojejunostomy after a standard
pancreaticoduodenectomy.
A better patient selection, preoperative optimisation, meticulous
intraoperative techniques and early recognition and aggressive
management of complications with utmost perioperative care helps to
improve the morbidity and hence prevent mortality after whipple’s
procedure.
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Name Age sex Abd_pain Jaundice Fever Pruritus Wt_loss CholangitisOthers DM HT BA Pre_surgeryN.V Veg Smoker Alc Icterus Pallor GB Liver Hb TC P L E ESR TB DB SAP Alb PT INR CA19-9 Liver_EchoIHBR CBD
Rajakannu 45 1 1 1 2 1 1 2 1 2 2 2 2 1 2 2 1 1 2 1 2 7.5 4600 70 15 5 68 3 2 243 2.9 11 0.91 13.8 1 1 1
rajendran 42 1 1 1 2 1 1 2 1 2 2 2 2 1 2 1 1 1 2 1 2 9 4800 80 12 6 26 16 8 436 3.6 14 1.16 120 1 1 1
singaram 62 1 1 1 2 2 2 2 2 1 2 2 2 1 2 1 1 1 2 1 2 10 5600 63 20 4 45 12 10 384 3.6 12 1 58 1 1 1
Subramani 58 1 1 1 1 1 1 1 2 2 2 2 2 1 2 2 1 1 2 1 1 8.6 14000 60 38 2 126 20.6 12.8 684 2.9 18 1.5 104 2 1 1
Deivasigamani68 1 1 2 2 2 1 2 2 1 1 2 2 1 2 1 1 2 2 2 2 10.2 6800 67 28 4 29 1.8 0.9 112 3.9 12 1 26 1 2 2
Vijaya 45 2 1 1 2 2 1 2 2 2 2 2 1 1 2 2 2 1 1 1 1 8.8 7600 64 30 6 54 14.6 7.4 256 3.6 13 1.08 82 1 1 1
Salomi 35 2 1 1 2 2 1 2 2 2 2 2 1 1 2 2 2 1 2 1 2 7.9 4300 73 24 3 77 16.2 6.9 186 3 12 1 18 1 1 1
Malar 30 2 1 1 1 1 1 1 1 2 2 2 2 1 2 2 2 1 2 1 1 8 18000 64 23 9 120 24.9 20.8 540 2.2 18 1.5 112 1 1 1
Parvathi 72 2 1 1 2 1 1 2 2 1 2 2 1 2 1 2 2 1 2 2 2 7 3400 70 28 2 33 12 8 120 3 12 1 20 1 1 2
Kalesha sherif47 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 12 4500 58 36 5 40 3 1.2 80 3.2 14 1.16 26 1 1 2
Yanathi 60 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 1 2 1 1 9.4 5400 60 34 6 46 16 12 420 3.8 12 1 21 1 1 1
Renganayaki 50 2 1 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 2 2 13.8 3600 64 30 1 50 18 14 680 3.6 13 1.08 38 2 1 1
Kumar 66 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 10.2 4800 66 34 4 80 14 12 720 2.8 14 1.16 22 1 1 1
Karunanidhi 54 1 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 1 1 13.2 6700 78 22 1 76 16 12 204 3.5 15 1.3 12 1 1 1
Chokkalingam72 1 1 1 1 1 1 1 2 1 1 2 2 1 2 1 1 1 2 1 1 12 12200 86 12 2 146 21 14.6 490 3 16 1.33 94 1 1 1
Chinnapillai 60 1 2 1 2 1 1 2 1 1 1 2 2 1 2 1 2 1 2 1 2 11 8700 67 31 4 56 16 12 324 3 14 1.16 22 1 1 1
Kesavan 40 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 9 880 58 32 8 50 19 16 200 3 12 1 30 1 1 1
Maragatham 60 2 1 1 2 1 1 2 2 2 2 2 1 2 1 2 2 1 1 1 2 7 4400 86 16 2 80 19 14 120 3.4 13 1.08 32 1 1 1
Krishnan 40 1 2 1 2 1 1 2 2 2 2 2 2 1 2 1 1 1 2 1 2 9 4300 76 22 4 45 19 14 256 2.8 14.6 1.2 33 1 1 1
Elumalai 69 1 1 1 1 1 1 1 2 1 2 2 2 1 2 1 1 1 1 1 1 7 3450 62 24 8 125 23.5 19 446 2.9 16 1.33 32 1 1 1
Maragatham 51 2 1 2 2 2 1 2 1 2 2 2 1 1 2 2 2 2 2 2 2 9.6 5800 72 22 4 45 0.33 0.11 452 4.1 10.09 0.8 32 1 1 1
Sathyanarayanan57 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 9 880 58 32 8 50 19 16 200 3 12 1 30 1 1 1
Babu 67 1 2 1 2 1 2 2 2 1 2 2 2 2 1 1 1 1 2 1 1 9.2 9400 82 12 3 45 20.6 17.2 316 3.6 15.7 1.3 62 1 1 1
Narasimman 60 1 2 1 2 1 1 2 2 2 2 2 2 2 1 1 1 1 2 1 1 9.8 3900 45 33 2 40 7.5 4.5 458 2.7 14.1 1.16 235.9 1 1 1
Rajammal 70 2 1 2 2 2 1 2 1 2 2 2 2 2 1 2 2 2 1 2 2 9.2 4800 48 42 6 72 0.7 0.3 72 3.2 13.1 1.11 20 1 1 1
Dhanabackiam45 2 1 1 2 1 1 2 2 2 2 2 1 1 2 2 2 1 2 1 2 12 6700 78 21 2 66 17 13 196 3.4 12 1 22 1 1 1
Samikannu 55 1 1 1 2 2 2 2 1 2 2 2 2 1 2 2 2 1 2 1 2 8.6 9200 76 21 3 60 2.9 1.7 256 2.8 14.6 1.2 30 1 1 1
Gunalan 65 1 2 1 2 1 1 2 2 1 2 2 2 1 2 2 2 1 2 1 2 9.6 5600 80 18 2 98 18 12 322 3 12 1 80 1 1 1
Premkumari 50 2 1 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 2 10.5 6500 73 23 9 67 15.5 11.8 105 3.6 15 1.25 67.74 1 1 1
Nawab john 68 1 2 1 2 1 1 2 2 1 1 2 2 1 2 1 1 1 2 1 2 10.2 7600 67 32 5 20 22 16.4 670 3 18 1.5 98 1 1 1
Ravi 48 1 1 1 2 1 1 2 2 2 2 2 2 1 2 1 1 1 2 1 2 13 4600 76 30 4 60 16 14.4 340 3.4 12 1 32 1 1 1
Thilagam 40 2 1 2 2 2 1 2 1 2 2 2 1 1 2 2 2 2 2 2 2 9.6 5800 72 22 4 45 0.33 0.11 452 4.1 10.09 0.8 32 1 1 1
Shankaran 40 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 9 880 58 32 8 50 19 16 200 3 12 1 30 1 1 1
Pujiammal 40 2 1 1 2 1 2 1 2 2 2 2 1 2 1 2 2 1 2 2 1 4.7 8300 75 19 3 24 21.9 13.8 293 3.2 11 1.02 26 2 1 1
Aravalli 40 2 1 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 2 10.5 6500 73 23 9 67 15.5 11.8 105 3.6 15 1.25 67.74 1 1 1
Vasantha 47 2 1 1 2 2 1 2 2 2 2 2 2 2 1 2 2 1 2 1 2 12 4500 76 22 4 34 17.8 12.4 120 3.2 12 1 20 1 1 1
sulochana 60 2 1 1 2 1 1 2 2 1 1 2 1 2 1 2 2 1 1 1 1 6.6 5600 70 22 8 55 19.8 11 420 2.9 15 1.25 26 1 1 1
Fathima beevi46 2 1 1 2 1 1 2 2 1 2 2 1 2 1 2 2 1 1 1 1 8 2300 68 33 6 102 18 10 336 2.6 19.6 1.64 112 1 1 1
Dhanabackiam36 2 1 1 2 1 1 2 2 1 2 2 2 1 2 2 2 1 2 1 2 11 6800 72 23 7 23 22 11 234 3 15 1.25 34 1 1 1
Sekar 47 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 1 12.8 7300 68 21 7 106 18 16 212 3 12 1 20 1 1 1
Viswanathan 45 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 1 1 2 1 2 9 880 58 32 8 50 19 16 200 3 12 1 30 1 1 1
Natarajan 40 1 1 1 2 1 1 2 2 2 2 2 2 1 2 2 1 2 1 2 1 10.2 4500 66 24 6 12 20 17.9 302 3.4 12 1 100.4 1 1 1
Gopal 58 1 1 1 2 1 1 2 2 2 2 2 2 1 2 1 1 1 2 1 2 13 4600 76 30 4 60 16 14.4 340 3.4 12 1 32 1 1 1
Subramani 58 1 1 1 2 2 1 2 2 2 2 2 2 2 1 1 1 1 2 1 1 12 4500 80 17 3 50 15.6 11.5 102 3 15 1.25 24 1 1 1
Sagadevan 45 1 2 1 2 1 1 2 1 2 2 2 2 1 2 2 2 1 2 1 1 9.4 10600 76 34 7 156 26.8 20.9 159 5.4 13 0.9 90 1 1 1
Krishnan 40 1 1 2 2 2 1 2 2 2 2 2 2 2 1 1 1 2 2 2 1 9.9 11600 73 17 10 40 1.2 0.6 96 3.3 15.9 1.22 50.4 2 1 1
Balasubramanian51 1 1 1 1 1 1 1 1 2 2 1 2 1 2 2 2 1 2 1 2 12 10200 62 38 4 112 29 18 441 3.9 11.2 0.89 30.2 1 1 1
selvam 46 1 1 1 2 1 1 2 2 2 2 2 2 1 2 2 1 1 2 1 1 8.3 12200 90 7 3 10 23 16 122 3.3 12 1 64 1 1 2
Saradha 50 2 1 1 1 1 1 1 1 2 2 2 2 1 2 2 2 1 2 1 1 14.2 10600 78 18 4 15 22 18 680 3.1 11.6 0.92 20 1 1 1
suseela 47 2 1 1 2 2 1 2 1 2 2 2 1 1 2 1 1 1 2 1 1 6.5 7400 81 8 1 64 18.5 11 139 2.9 17.4 1.45 32 1 1 1
Mass OGD size VAS MRI Pre_Biliary_drainBiopsy Ampullary Pancreas Distal CBD Duo_carcinomaDur_surgeryBlood_loss Trans Tech RT Urinary DT Serum_amylaseDT_amylaseCBC LFT stay DGE Hae leak Intra_abd_collWound PneumonitisUTI Mortality
2 1 2 2 2 1 2 2 2 2 10 800 2 1 7 6 8 84 68 1 1 15 2 2 4 2 1 2 2 2
1 1 2.6 2 2 2 2 2 1 2 2 5 200 0 2 8 10 12 96 54 1 1 16 2 2 4 2 2 2 2 2
2 1 1 2 2 2 1 1 2 2 2 5 250 0 2 12 8 14 120 100 1 1 14 1 2 4 1 1 1 2 2
2 1 1.5 2 1 1 1 1 2 2 2 4.5 100 0 2 9 7 10 120 86 1 1 12 2 2 4 2 1 2 2 2
2 1 2.6 2 2 2 2 2 1 2 2 5 80 0 2 11 8 14 102 450 1 1 18 1 2 2 1 1 2 2 2
2 1 1.1 2 2 2 1 1 2 2 2 5 120 0 2 7 5 10 102 50 1 1 12 2 2 4 2 2 2 2 2
2 1 1.5 2 1 2 1 1 2 2 2 4 80 0 2 7 4 9 86 42 1 1 11 2 2 4 2 2 2 2 2
2 1 1 2 1 1 1 2 2 2 1 6 200 0 2 9 4 8 24 36 1 1 14 2 2 4 2 2 2 2 2
2 1 3 22 2 2 1 1 2 2 2 6 100 0 2 8 7 9 40 80 1 1 10 2 2 4 2 2 2 2 2
2 1 1 2 2 2 1 2 1 2 2 4 100 0 2 8 4 9 30 66 1 1 12 2 2 4 2 2 2 2 2
2 1 2 2 2 2 1 1 2 2 2 6 120 0 2 6 8 9 40 36 1 1 12 2 2 4 2 2 2 2 2
1 1 3 2 2 2 1 2 2 1 2 6 100 0 2 7 6 8 32 74 1 1 14 2 2 4 2 2 2 2 2
2 1 2.2 2 2 2 2 2 2 2 1 6 200 0 2 8 5 9 26 58 1 1 13 2 2 4 2 2 2 2 2
1 1 3.2 2 2 2 2 1 2 2 2 6 200 0 2 9 5 10 20 27 1 1 12 2 2 4 2 2 2 2 2
2 1 2.2 2 1 2 1 1 2 2 2 8 1050 3 2 0 0 0 0 0 0 0 0 2 1 3 1 2 2 2 1
2 1 2 2 2 2 2 2 1 2 2 7 220 0 2 9 12 10 23 46 1 1 18 2 2 4 2 1 1 1 2
2 1 2 2 2 2 1 1 2 2 2 6 100 0 2 6 8 9 34 64 1 1 14 2 2 4 2 2 2 2 2
2 1 4 2 2 2 2 2 1 2 2 4 100 0 2 6 4 9 24 36 1 1 14 2 2 4 2 2 2 2 2
2 1 1.2 2 2 2 1 1 2 2 2 5 200 0 2 8 9 20 45 680 1 1 20 2 2 2 1 1 2 2 2
2 1 2 2 1 1 1 1 2 2 2 6 560 0 2 8 7 10 34 58 1 1 12 2 2 4 2 1 2 2 2
1 1 2 2 2 2 1 1 2 2 2 4 150 0 1 11 9 14 45 160 1 1 16 1 2 1 2 2 2 2 2
2 1 2 2 2 2 1 2 1 2 2 6 100 0 2 6 8 9 34 64 1 1 14 2 2 4 2 2 2 2 2
2 1 2 2 2 2 1 1 2 2 2 4 200 0 1 10 9 15 86 46 1 1 16 1 2 1 2 2 2 2 2
1 1 2.6 2 2 2 2 2 1 2 2 6 200 2 1 8 7 6 6 10 2 1 13 2 2 4 2 1 2 2 2
1 1 4 2 2 2 1 2 1 2 2 6 100 0 1 5 4 9 48 24 1 1 11 2 2 4 2 2 2 2 2
2 1 3 2 2 2 1 2 1 2 2 4 150 0 1 5 4 8 35 80 1 1 12 2 2 4 2 2 2 2 2
1 1 3 2 1 1 2 1 2 2 2 3.5 800 1 1 7 6 8 620 410 2 1 10 2 2 4 2 2 2 2 2
1 1 2 2 2 2 1 1 2 2 2 6 200 0 1 6 8 9 45 85 1 1 12 2 2 4 2 1 2 1 2
2 1 3 2 2 2 1 1 2 2 2 6 200 0 1 8 7 9 60 45 1 1 10 2 2 4 2 2 2 2 2
2 1 3 2 1 1 1 2 1 2 2 7 800 2 1 9 6 11 50 102 1 1 15 2 2 4 2 1 2 1 2
2 1 4 2 2 2 1 2 2 1 2 6 200 0 1 7 6 9 42 50 1 1 14 2 2 4 2 2 2 2 2
1 1 2 2 2 2 1 1 2 2 2 4 150 0 1 11 9 14 45 160 1 1 16 1 2 4 2 2 2 2 2
2 1 2 2 2 2 1 2 1 2 2 6 100 0 2 6 8 9 34 64 1 1 14 2 2 4 2 2 2 2 2
1 1 1.3 2 2 2 1 1 2 2 2 4 400 0 1 6 7 9 123 35 1 1 11 2 2 4 2 2 2 2 2
2 1 3 2 2 2 1 1 2 2 2 6 200 0 1 8 7 9 60 45 1 1 10 2 2 4 2 2 2 2 2
2 1 1 2 2 2 1 1 2 2 2 6 150 0 1 8 6 9 45 46 1 1 12 2 2 4 2 2 2 2 2
2 1 1 2 2 2 1 1 2 2 2 7 560 4 2 0 0 0 0 0 0 0 0 0 1 3 1 2 1 2 1
2 1 1.2 2 1 2 1 1 2 2 2 8 450 3 1 0 0 0 0 0 0 0 0 0 1 3 1 2 2 2 1
1 1 2.8 2 1 1 1 1 2 2 2 7 550 4 1 0 0 0 0 0 0 0 0 0 1 3 1 2 2 2 1
2 1 2.8 2 2 2 1 1 2 2 2 8 900 3 2 14 12 16 102 800 2 1 18 1 2 2 2 1 2 2 2
2 1 2 2 2 2 1 1 2 2 2 6 100 0 2 6 8 9 34 64 1 1 14 2 2 2 2 2 2 2 2
2 1 3.4 2 1 2 1 1 2 2 2 8 800 4 2 15 12 18 66 560 2 1 20 1 2 2 1 2 2 1 2
2 1 4 2 2 2 1 1 2 2 2 6 200 0 1 7 6 9 42 50 1 1 14 2 2 1 2 2 2 2 2
2 1 1.5 2 2 2 1 1 2 2 2 5 150 0 1 8 5 10 58 69 1 1 12 2 2 4 2 2 2 2 2
1 1 2.8 2 1 2 1 1 2 2 2 7 1100 2 1 16 6 8 55 170 1 1 17 1 2 1 2 2 2 2 2
1 1 8 1 2 2 1 2 1 2 2 11 4650 7 1 12 10 16 13 8297 2 2 20 1 2 3 1 2 2 2 2
1 1 2 2 1 1 1 1 2 2 2 9 300 2 1 6 10 11 32 24 1 1 15 2 2 2 2 2 2 2 2
1 1 2 2 2 1 1 1 2 2 2 5 300 0 2 9 6 8 45 349 1 1 12 2 2 1 2 2 2 2 2
1 1 1.3 2 2 1 1 2 2 1 2 5 600 0 1 6 4 12 28 21 1 1 16 2 2 2 2 1 2 2 2
1 1 3.4 2 2 2 1 2 1 2 2 7 500 0 1
